ES2659161T3 - Proteína de fusión de transferrina-tumstatina y métodos para producir y usar la misma - Google Patents

Proteína de fusión de transferrina-tumstatina y métodos para producir y usar la misma Download PDF

Info

Publication number
ES2659161T3
ES2659161T3 ES12824616.2T ES12824616T ES2659161T3 ES 2659161 T3 ES2659161 T3 ES 2659161T3 ES 12824616 T ES12824616 T ES 12824616T ES 2659161 T3 ES2659161 T3 ES 2659161T3
Authority
ES
Spain
Prior art keywords
tumstatin
transferrin
protein
recombinant protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12824616.2T
Other languages
English (en)
Spanish (es)
Inventor
Uday B. Kompella
Robert I. SCHEINMAN
Puneet Tyagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Application granted granted Critical
Publication of ES2659161T3 publication Critical patent/ES2659161T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES12824616.2T 2011-08-17 2012-08-15 Proteína de fusión de transferrina-tumstatina y métodos para producir y usar la misma Active ES2659161T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524508P 2011-08-17 2011-08-17
US201161524508P 2011-08-17
PCT/US2012/051013 WO2013025846A2 (en) 2011-08-17 2012-08-15 Transferrin-tumstatin fusion protein and methods for producing and using the same

Publications (1)

Publication Number Publication Date
ES2659161T3 true ES2659161T3 (es) 2018-03-14

Family

ID=47715692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12824616.2T Active ES2659161T3 (es) 2011-08-17 2012-08-15 Proteína de fusión de transferrina-tumstatina y métodos para producir y usar la misma

Country Status (15)

Country Link
US (1) US9290562B2 (cg-RX-API-DMAC7.html)
EP (1) EP2744831B1 (cg-RX-API-DMAC7.html)
JP (1) JP6073888B2 (cg-RX-API-DMAC7.html)
CN (2) CN103998470A (cg-RX-API-DMAC7.html)
AU (1) AU2012296588B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008680A2 (cg-RX-API-DMAC7.html)
CA (1) CA2849015C (cg-RX-API-DMAC7.html)
DK (1) DK2744831T3 (cg-RX-API-DMAC7.html)
ES (1) ES2659161T3 (cg-RX-API-DMAC7.html)
NO (1) NO2820418T3 (cg-RX-API-DMAC7.html)
PL (1) PL2744831T3 (cg-RX-API-DMAC7.html)
PT (1) PT2744831T (cg-RX-API-DMAC7.html)
SI (1) SI2744831T1 (cg-RX-API-DMAC7.html)
TR (1) TR201802686T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013025846A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180288A1 (zh) * 2013-05-06 2014-11-13 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
WO2014203182A1 (en) * 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating choroidal neovascularisation
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR101818151B1 (ko) 2016-03-25 2018-01-16 한국과학기술원 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US20050192242A1 (en) 1995-10-11 2005-09-01 Neal Zane C. Therapeutic fusion protein transgenes
CA2331332A1 (en) * 1998-06-17 1999-12-23 Raghuram Kalluri Anti-angiogenic proteins and methods of use thereof
JP2003517847A (ja) 1999-12-23 2003-06-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド トランスフェリンポリヌクレオチド、ポリペプチド、および抗体
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
NZ534310A (en) * 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
EP1670428A4 (en) 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
WO2006044614A2 (en) 2004-10-14 2006-04-27 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
EP2468294A1 (en) 2006-02-03 2012-06-27 Crc For Asthma And Airways Ltd A method of modulating cellular activity and agents for use therein
CN101070349B (zh) * 2007-05-22 2010-10-13 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
JP6101638B2 (ja) 2011-03-03 2017-03-22 ザイムワークス，インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物

Also Published As

Publication number Publication date
WO2013025846A2 (en) 2013-02-21
TR201802686T4 (tr) 2018-03-21
JP2014526890A (ja) 2014-10-09
CA2849015C (en) 2017-08-08
NO2820418T3 (cg-RX-API-DMAC7.html) 2018-05-05
EP2744831A2 (en) 2014-06-25
PL2744831T3 (pl) 2018-05-30
JP6073888B2 (ja) 2017-02-01
SI2744831T1 (en) 2018-04-30
US9290562B2 (en) 2016-03-22
PT2744831T (pt) 2018-03-05
DK2744831T3 (en) 2018-03-05
US20140179612A1 (en) 2014-06-26
AU2012296588B2 (en) 2017-07-27
AU2012296588A1 (en) 2014-04-03
CA2849015A1 (en) 2013-02-21
CN103998470A (zh) 2014-08-20
EP2744831A4 (en) 2015-03-11
EP2744831B1 (en) 2017-12-06
BR112014008680A2 (pt) 2017-06-13
CN110105453A (zh) 2019-08-09
WO2013025846A3 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
JP5858285B2 (ja) キャリアペプチドフラグメント及びその利用
ES2361621T7 (es) Peptidos de lactoferrina utiles como peptidos de penetracion celular.
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
US20220287968A1 (en) Lipid vesicle-mediated delivery to cells
ES2659161T3 (es) Proteína de fusión de transferrina-tumstatina y métodos para producir y usar la misma
US9102763B2 (en) Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
KR101258279B1 (ko) 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
ES2621337T3 (es) Desarrollo de nuevo dominio de transducción macromolecular con mejor permeabilidad celular y método de uso del mismo
US20220265843A1 (en) Extracellular vesicle-mediated delivery to cells
WO2007093975A2 (es) Uso del factor pedf para inducir la renovación de células
Darche et al. Antagonist of nucleolin, N6L, inhibits neovascularization in mouse models of retinopathies
Kumar et al. Cell-Penetrating chaperone Nuc1 for Small-and Large-Molecule delivery into retinal cells and tissues
US20230340024A1 (en) Novel peptide, compositions and method for delivery of agents into cells and tissues
CN112274631A (zh) 重组蛋白Semaphorin3G在防治视网膜疾病中的医药用途
Talreja et al. G-quartet oligonucleotide mediated delivery of functional X-linked inhibitor of apoptosis protein into retinal cells following intravitreal injection
US20230128981A1 (en) Cd24-loaded vesicles for treatment of cytokine storm and other conditions
Piroozmand et al. MiRGD peptideticle targeted delivery of hinge-truncated soluble VEGF receptor 1 fusion protein to the retinal pigment epithelium cell line and newborn mice retina
US20230123615A1 (en) Methods of treatment and novel constructs
WO2014015338A1 (en) Acetylated crystallin polypeptides and mimetics thereof as therapeutics agents